Category: seralutinib
-
Gossamer Bio a new outperform at Oppenheimer on seralutinib for PAH
•
George Clerk Oppenheimer launched Gossamer Bio into an outperformance expressing optimism about seralutinib, an inhaled tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The company has a price target of $9 (~984% upside based on June 24 close). Analyst Andreas Argyrides said that the safety of the…